` CDT (Conduit Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

C
CDT
vs
S&P 500

Over the past 12 months, CDT has underperformed S&P 500, delivering a return of -99% compared to the S&P 500's +15% growth.

Stocks Performance
CDT vs S&P 500

Loading
CDT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CDT vs S&P 500

Performance Gap Between CDT and GSPC
HIDDEN
Show

Performance By Year
CDT vs S&P 500

Loading
CDT
S&P 500
Add Stock

Competitors Performance
Conduit Pharmaceuticals Inc vs Peers

Conduit Pharmaceuticals Inc
Glance View

Market Cap
4m USD
Industry
N/A

Conduit Pharmaceuticals Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2022-02-03. Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The firm is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. The company is used as a treatment option for Hashimoto’s Thyroiditis (HT) and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).

CDT Intrinsic Value
Not Available
Back to Top